top of page


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
24/09/2026 aTyr Pharma aligned with FDA on Phase 3 study of efzifitimod in pulmonary sarcoidosis Kyverna reported 1-year data for miv-cel in SPS and gMG aTyr Pharma aligned with FDA on Phase 3 study of efzifitimod in pulmonary sarcoidosis (Ref) aTyr Pharma reached alignment with the US FDA on the Ph3 protocol for efzofitimod (an immunomodulator) in patients with chronic symptomatic pulmonary sarcoidosis with restrictive lung disease. The company will initially focus on regula
decodeMR Team
Sep 291 min read
Â
bottom of page